ArticleJournal of translational medicine2026
Improving pancreatic adenocarcinoma prognosis models through ligand receptor interactions and histopathological integration.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreatic adenocarcinoma (PAAD) has an extremely poor prognosis, and existing prognostic markers fail to fully capture the complex heterogeneity of the tumor microenvironment. This study aimed to integrate ligand-receptor (L-R) interactions, multi-omics data, and deep learning-based pathological images to construct an interpretable multimodal prognostic model and to elucidate the mechanisms underlying the cancer-associated fibroblast (CAF) microenvironment.
methodsSignificant L-R interactions were identified using BulkSignalR, followed by sequential Cox, least absolute shrinkage and selection operator (LASSO)-Cox, and random survival forest analyses to construct a prognostic model. Multi-omics profiling characterized molecular distinctions between risk groups. Key L-R pairs were evaluated with single-cell and spatial transcriptomics, validated in 39 paired clinical specimens via immunofluorescence, and linked to histopathological features through deep learning on hematoxylin and eosin-stained whole-slide images.
resultsWe identified 236 significant L-R pairs, with 47 associated with prognosis. Integration of LASSO-Cox and random survival forest analyses yielded five key pairs: IL16_KCND1, PLAU_ITGA5, FN1_ITGB3, GNAS_ADCY1, and CALM1_PDE1B. The resulting risk model effectively stratified overall survival. The high-risk group showed higher tumor mutational burden, more frequent KRAS and TP53 mutations, and enrichment of extracellular matrix remodeling, transforming growth factor‑β signaling, and glycolysis pathways. Single-cell and spatial analyses revealed preferential enrichment of PLAU_ITGA5 and FN1_ITGB3 in fibroblast-related compartments. Immunofluorescence confirmed upregulation of these pairs in tumor tissues, and deep learning identified fibroblast-associated histopathological features with strong concordance to the risk axes.
conclusionsThis study established the first multimodal prognostic framework integrating L-R interactions and histopathological features, revealing the central role of CAF-mediated L-R signaling in remodeling the PAAD microenvironment and providing a novel strategy for precise prognostic stratification and targeted microenvironmental therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.